12:00 AM
 | 
Jan 16, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xalkori crizotinib regulatory update

Pfizer said the Korea Food and Drug Administration approved Xalkori crizotinib to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients whose tumors are anaplastic lymphoma...

Read the full 131 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >